Method and kit for producing induced pluripotent stem cells
A novel method using reprogramming factors and specific culture conditions effectively establishes iPS cells from pluripotency-resistant mammals, achieving marker expression and differentiation capabilities.
Patent Information
- Application Number
- JP2021514245
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-17
- Filing Date
- 2020-04-17
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2040-04-17
AI Technical Summary
Establishing induced pluripotent stem cells (iPS cells) from certain mammalian species, such as dogs, pigs, marmosets, and ferrets, is particularly challenging due to their resistance to pluripotency induction.
A method involving the introduction of reprogramming factors like OCT family, SOX family, KLF family, MYC family, LIN28 family, and P53 function inhibitors into mammalian somatic cells, followed by culturing in a neural stem cell culture medium and then a growth medium, using specific inhibitors and growth factors to achieve induced pluripotent stem cells.
This method successfully establishes iPS cells from pluripotency-resistant animals, demonstrating expression of pluripotent markers and the ability to differentiate into various cell types, including teratomas, with no residual vectors detected.
Smart Images

Figure 0007591219000005 
Figure 0007591219000006 
Figure 0007591219000007
Abstract
Description
[Technical field]
[0001] The present invention relates to a method and kit for producing induced pluripotent stem cells. This application claims priority based on Japanese Patent Application No. 2019-078907, filed on April 17, 2019, the contents of which are incorporated herein by reference. [Background technology]
[0002] The technology for generating iPS cells from human and mouse somatic cells has been improved and simplified, and the efficiency of generating iPS cells has improved. However, there are animals (animals resistant to pluripotency induction) for which it is difficult to generate iPS cells, especially from adult somatic cells. Known animals resistant to pluripotency induction include dogs, pigs, marmosets, cats, cows, and horses.
[0003] For example, canine iPS cells can be established by persistently expressing reprogramming factors in canine fetal fibroblasts (see, for example, Non-Patent Document 1). Canine iPS cells can also be established from canine fetal fibroblasts by using Sendai virus (see, for example, Non-Patent Document 2). Porcine iPS cells can also be established by persistently expressing reprogramming factors in porcine fetal fibroblasts (see, for example, Non-Patent Document 3). [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Nishimura T et al., Feeder-independent canine induced pluripotent stem cells maintained under serum-free conditions. Mol. Reprod. Dev., vol. 84, 329-339, 2017. [Non-Patent Document 2] Tsukamoto M et al., Generation of Footprint-Free Canine Induced Pluripotent Stem Cells Using Auto-Erasable Sendai Virus Vector. Stem Cells Dev., 27, 1577-1586, 2018. [Non-Patent Document 3] Du X et al., Barriers for Deriving Transgene-Free Pig iPS Cells with Episomal Vectors. Stem Cells, vol.33, 3228-3238, 2015. Summary of the Invention [Problem to be solved by the invention]
[0005] An object of the present invention is to provide a new technique for establishing iPS cells from mammalian somatic cells. [Means for solving the problem]
[0006] The present invention includes the following aspects. [1] A method for producing induced pluripotent stem cells, comprising the steps of: introducing reprogramming factors into mammalian somatic cells, and culturing the cells in a neural stem cell culture medium to obtain induced neural stem cell-like cells; and culturing the induced neural stem cell-like cells in a proliferation medium to obtain induced pluripotent stem cells, wherein the reprogramming factors include the OCT family, the SOX family, the KLF family, the MYC family, the LIN28 family, and a P53 function inhibitor. [2] The method for producing induced pluripotent stem cells described in [1], wherein the reprogramming factors further include one or more selected from the group consisting of the KDM family, the GLIS family, and NANOG. [3] The method of producing the present invention described in [1] or [2], wherein the somatic cells are derived from adults. [4] The method for producing a neural stem cell according to any one of [1] to [3], wherein the neural stem cell culture medium contains a MAP kinase inhibitor, a GSK3β inhibitor and a TGFβ inhibitor. [5] The method according to any one of [1] to [4], wherein the growth medium contains bFGF. [6] An induced pluripotent stem cell produced by the production method described in any one of [1] to [5]. [7] A kit for producing induced pluripotent stem cells from somatic cells of a pluripotent induction-resistant animal, comprising: reprogramming factors including an OCT family member, a SOX family member, a KLF family member, a MYC family member, a LIN28 family member, and a P53 function inhibitor; and a neural stem cell culture medium including a MAP kinase inhibitor, a GSK3β inhibitor, and a TGFβ inhibitor. [8] The kit described in [7], wherein the reprogramming factors further include one or more selected from the group consisting of the KDM family, the GLIS family, and NANOG. [9] The kit described in [7] or [8], further comprising a growth medium containing bFGF. Effect of the Invention
[0007] According to the present invention, a new technique for establishing iPS cells from mammalian somatic cells can be provided. [Brief description of the drawings]
[0008] [Figure 1] FIG. 1 is a schematic diagram showing an EP-A vector set for expressing reprogramming factors. [Diagram 2] FIG. 1 is a schematic diagram showing an EP-B vector set for expressing reprogramming factors. [Diagram 3] (a) and (b) are photographs of cells in Experimental Example 1. (a) is a bright-field photograph of cells that were transfected with an EP-A vector set and cultured in a growth medium for four days. (b) is a photograph of EGFP fluorescence of cells that were transfected with an EP-A vector set and cultured in a growth medium for four days. [Figure 4](a) and (b) are photographs of cells in Experimental Example 1. (a) is a photograph of cells into which the EP-A vector set was introduced into E01F and cultured in a growth medium for 30 days. Fig. 4(b) is a photograph of cells into which the EP-A vector set was introduced into E02M and cultured in a growth medium for 30 days. [Diagram 5] FIG. 1 shows the steps for establishing iPS cells from marmoset somatic cells. [Figure 6] (a) to (d) are photographs of iNSL cells in Experimental Example 2. (a) is a photograph of a colony formed after E01F was introduced with an EP-A vector set and then cultured in neural stem cell culture medium. (b) is a photograph of a colony formed after E01F was introduced with an EP-B vector set and then cultured in neural stem cell culture medium. (c) is a photograph of a colony formed after E02M was introduced with an EP-A vector set and then cultured in neural stem cell culture medium. (d) is a photograph of a colony formed after E02M was introduced with an EP-B vector set and then cultured in neural stem cell culture medium. [Figure 7] 1 is a graph showing the results of calculating colony-forming ability when marmoset embryonic fibroblasts were used in Experimental Example 2. [Figure 8] (a) and (b) are diagrams showing the results of alkaline phosphatase staining in Experimental Example 2. (a) is a diagram showing the results of alkaline phosphatase staining of colonies obtained by introducing an EP-A vector set into E01F and culturing in a neural stem cell culture medium. (b) is a diagram showing the results of alkaline phosphatase staining of colonies obtained by introducing an EP-B vector set into E01F and culturing in a neural stem cell culture medium. [Figure 9]Photographs of iNSL cells and iPS cells in Experimental Example 3. (a) is a photograph of a colony formed by introducing an EP-A vector set into marmoset embryonic fibroblasts (E01F) and culturing them in neural stem cell culture medium. (b) is a photograph of a colony formed by introducing an EP-A vector set into marmoset embryonic fibroblasts (E01F) and culturing them in neural stem cell culture medium and then in proliferation medium. (c) is a photograph of a colony formed by introducing an EP-B vector set into marmoset embryonic fibroblasts (E02M) and culturing them in neural stem cell culture medium. (d) is a photograph of a colony formed by introducing an EP-B vector set into marmoset embryonic fibroblasts (E02M) and culturing them in neural stem cell culture medium and then in proliferation medium. [Figure 10] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells in Experimental Example 3. [Figure 11] FIG. 13 shows the results of alkaline phosphatase staining of marmoset iPS cells in Experimental Example 3. [Figure 12] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells in Experimental Example 3. [Figure 13] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells in Experimental Example 3. [Figure 14] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells in Experimental Example 3. [Figure 15] FIG. 13 shows the results of an analysis of the presence or absence of an expression vector in marmoset iPS cells in Experimental Example 3. [Figure 16] FIG. 13 shows the results of an analysis of marker expression in the three germ layers differentiated from marmoset iPS cells in Experimental Example 4. [Figure 17] FIG. 13 shows the results of analyzing the expression of AFP expressed by marmoset iPS cells cultured in KSR medium in Experimental Example 4. [Figure 18]FIG. 13 shows the results of analyzing the expression of AFP expressed by marmoset iPS cells cultured in a medium containing FBS in Experimental Example 4. [Figure 19] FIG. 13 shows the results of analysis of teratomas formed from marmoset iPS cells in Experimental Example 4. [Figure 20] 13 is a photograph of iNSL cells derived from adult marmoset fibroblasts in Experimental Example 5. [Figure 21] FIG. 13 is a graph showing the colony-forming ability of iNSL cells derived from adult marmoset fibroblasts in Experimental Example 5. [Figure 22] FIG. 13 shows the results of alkaline phosphatase staining of iNSL cells derived from adult marmoset fibroblasts in Experimental Example 5. [Figure 23] 13 is a photograph of a colony of marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Figure 24] FIG. 13 shows the results of alkaline phosphatase staining of iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Diagram 25] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Figure 26] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Figure 27] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Figure 28] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Figure 29] FIG. 13 shows the results of an analysis of the expression of ES cell markers in marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Diagram 30] FIG. 13 shows the results of an analysis of marker expression in three germ layers differentiated from marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Diagram 31] FIG. 13 shows the results of an analysis of marker expression in three germ layers differentiated from marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Diagram 32] FIG. 13 shows the results of analyzing teratomas formed from marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Diagram 33] FIG. 13 shows the results of an analysis of whether a vector remains in marmoset iPS cells derived from adult marmoset fibroblasts in Experimental Example 5. [Diagram 34] 13 is a photograph of marmoset iNSL cells in Experimental Example 6. [Diagram 35] FIG. 13 shows the results of an analysis of remaining vectors in marmoset iNSL cells in Experimental Example 6. [Diagram 36] FIG. 13 shows the results of analyzing the expression of endogenous OCT4, NANOG, SOX2, KLKF4, and ZFP42 in marmoset iNSL cells in Experimental Example 6. [Figure 37] FIG. 13 shows the results of analyzing the expression of DPPA5 and TERT in marmoset iNSL cells in Experimental Example 6. [Figure 38] FIG. 13 shows the results of analyzing the expression of endogenous and exogenous OCT4, NANOG, KLF4, and Lin28 in marmoset iNSL cells in Experimental Example 6. [Figure 39] FIG. 13 shows the results of analyzing the expression of PAX6 in marmoset iNSL cells in Experimental Example 6. [Diagram 40] FIG. 13 shows the results of analyzing the expression of SOX1 and ZFP521 in marmoset iNSL cells in Experimental Example 6. [Diagram 41] FIG. 13 shows the results of analyzing the expression of T and SOX17 in marmoset iNSL cells in Experimental Example 6. [Diagram 42] 1 shows the schedule for the neuronal differentiation assay in Experimental Example 6. [Diagram 43] FIG. 13 shows the results of Hoechst staining and immunostaining with anti-βIII-tubulin antibody of cells differentiated from the obtained induced neural stem cells in Experimental Example 6. [Diagram 44] 13 is a graph showing the percentage of cells in which expression of βIII-tubulin was observed among cells differentiated into nerve cells in Experimental Example 6. [Diagram 45] FIG. 13 is a diagram showing the results of clustering analysis in Experimental Example 7. [Figure 46] FIG. 13 shows the results of analyzing gene expression levels in Experimental Example 7. [Figure 47] FIG. 13 is a diagram showing the results of principal component analysis in Experimental Example 7. [Figure 48] 13 is a photograph of a colony formed by canine iPS cells in Experimental Example 8. [Figure 49] FIG. 13 shows the results of analyzing the expression of OCT4, SOX2, and NANOG in canine iPS cells in Experimental Example 8. [Figure 50] 13 is a photograph of a teratoma formed from canine iPS cells in Experimental Example 8. [Figure 51] FIG. 13 shows the results of analysis of bone, cartilage, nerve cells, retina, sebaceous gland, hair follicle epithelium, and glandular tissue in a teratoma formed from canine iPS cells in Experimental Example 8. [Figure 52] FIG. 13 shows the results of an analysis of whether or not a vector remains in canine iPS cells in Experimental Example 8. [Diagram 53] 13 is a photograph of a colony of porcine iPS cells in Experimental Example 9. [Figure 54] FIG. 13 shows the results of analyzing the expression of OCT4, SOX2, and NANOG in porcine iNSL cells and porcine iPS cells in Experimental Example 9. [Figure 55] 13 is a photograph of a colony of ferret iPS cells in Experimental Example 10. [Figure 56]FIG. 13 shows the results of analyzing the expression of OCT4, SOX2, and NANOG in ferret iNSL cells and ferret iPS cells in Experimental Example 10. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] [Gene and protein names] In this specification, human genes and human proteins, and genes and proteins of pluripotency-induced resistant animals are represented by capital letters. However, in some cases, human genes and genes of other species may be represented by capital letters without strict distinction. In addition, human proteins and proteins of other species may be represented by capital letters without strict distinction.
[0010] In this specification, for example, the term "SOX2" refers to both the SOX2 protein and the nucleic acid encoding it. In addition, for example, the term "reprogramming factor" refers to both the reprogramming protein and the nucleic acid encoding it. In addition, for example, the term "SOX family" refers to both the SOX protein and the nucleic acid encoding it.
[0011] [Cell name] In this specification, induced pluripotent stem cells may be referred to as iPS cells or iPSCs, and induced neural stem cell like cells may be referred to as iNSL cells or iNSLCs.
[0012] [Manufacturing method] In one embodiment, the present invention provides a method for producing induced pluripotent stem cells, comprising the steps of: (a) introducing reprogramming factors into mammalian somatic cells and culturing the cells in a neural stem cell culture medium to obtain induced neural stem cell-like cells; and (b) culturing the induced neural stem cell-like cells in a proliferation medium to obtain induced pluripotent stem cells, wherein the reprogramming factors include the OCT family, the SOX family, the KLF family, the MYC family, the LIN28 family, and a P53 function inhibitor. In this embodiment, the mammal may be an animal resistant to pluripotent induction.
[0013] As used herein, an animal resistant to pluripotency induction refers to a mammal in which iPS cells cannot be established even when a combination of reprogramming factors of the OCT family, SOX family, KLF family, and MYC family is expressed in the adult somatic cells of the animal.
[0014] Examples of pluripotent induction-resistant animals include, but are not limited to, monkeys, pigs, ferrets, sheep, cats, dogs, horses, cows, goats, rabbits, etc. Examples of monkeys include marmosets.
[0015] In this embodiment, somatic cells of an animal resistant to pluripotency induction used as a material for producing iPS cells include, for example, fetal somatic cells and adult somatic cells. Examples of somatic cells include fat cells, chondrocytes, osteoblasts, bone cells, muscle cells, vascular cells, immune cells, epithelial cells, nerve cells, hepatic cells, pancreatic cells, and precursor cells thereof. The above-mentioned somatic cells may be undifferentiated cells or differentiated cells.
[0016] Marmosets, dogs, pigs, and ferrets are representative animals resistant to pluripotency induction. As described below in the Examples, the production method of this embodiment can be used to transiently express reprogramming factors in adult somatic cells of marmosets, dogs, pigs, and ferrets to establish iPS cells that do not have an expression construct that expresses the reprogramming factors in the cells.
[0017] In this embodiment, it is preferable to introduce a non-episomal vector carrying a nucleic acid encoding EBNA-1 together with the reprogramming factors into mammalian somatic cells.
[0018] (initialization factor) In this embodiment, the reprogramming factors include the OCT family, the SOX family, the KLF family, the MYC family, the LIN28 family, and a P53 function inhibitor.
[0019] Examples of the OCT family include OCT3 / 4, OCT1, OCT2, OCT6, etc. As the OCT family, OCT3 / 4 is preferred.
[0020] Examples of the SOX family include SOX2, SOX1, SOX3, SOX15, and SOX17.
[0021] Examples of the KLF family include KLF1, KLF2, KLF4, and KLF5.
[0022] Examples of the MYC family include C-MYC, N-MYC, L-MYC, etc.
[0023] The LIN28 family includes LIN28, LIN28B, and the like.
[0024] NANOG is a transcription factor that has a homeodomain. When NANOG is expressed in somatic cells together with OCT4, SOX2, and LIN28, iPS cells can be established (see, for example, Yu J et al., Science, 318, 1917-1920 (2007)).
[0025] In this specification, the term "P53 function inhibitor" refers to any substance that inhibits the function of P53 protein or inhibits the expression of P53 gene (for example, WO 2009 / 157593).
[0026] Substances that suppress the function of the P53 protein include dominant-negative mutants of P53, chemical substances that inhibit the function of the P53 protein, anti-P53 antagonist antibodies, decoy nucleic acids containing the consensus sequence of the P53 response element, inhibitors of the P53 pathway, and the like.
[0027] Substances that suppress the expression of the P53 gene include siRNA, shRNA, and the like against P53.
[0028] A preferred dominant-negative mutant of P53 is P53DD, which lacks amino acids at positions 14-301 of mouse P53 (corresponding to positions 11-304 of human P53) (see, for example, Bowman, T., Genes & Development, 10, 826-835 (1996)).
[0029] The reprogramming factors may further include one or more selected from the group consisting of the KDM family, the GLIS family, and NANOG. The reprogramming factors preferably include the OCT family, the SOX family, the KLF family, the MYC family, the LIN28 family, a P53 function inhibitor, the KDM family, the GLIS family, and NANOG.
[0030] The KDM family has lysine demethylase activity and demethylates K9 of histone H3. The KDM family includes KDM1, KDM2, KDM3, KDM4, KDM5, and KDM6. Forced expression of KDM4D or KDM4A demethylates the 9th lysine residue of histone H3 and promotes somatic cell reprogramming (see, for example, Matoba et al., Cell, 159, 884-895 (2014); Chung YG et al., Cell Stem Cell, 17, 758-766 (2015)).
[0031] The KDM family used as the reprogramming factor is not particularly limited, and examples thereof include KDM1, KDM2, KDM3, KDM4, KDM5, and KDM6. As the KDM family, KDM4A and KDM4D are preferred.
[0032] The GLIS family (GLI Similar family) is a zinc finger type transcription factor. The GLIS family consists of GLIS1, GLIS2, and GLIS3. Forced expression of GLIS1 promotes the formation of iPS cells (see, for example, Maekawa et al., Nature, 474, 225-229 (2011)). In addition, GLIS1, GLIS2, and GLIS3 play diverse roles in stem cells (see, for example, Scoville DW et al., Stem Cell Investig, 4:80 (2017)).
[0033] The GLIS family used as the reprogramming factor is not particularly limited, and examples thereof include GLIS1, GLIS2, and GLIS3. As the GLIS family, GLIS1 is preferred.
[0034] The reprogramming factor may include the ESRR family.
[0035] The ESRR family (Estrogen-related receptor family) is a nuclear receptor. As the ESRR family, ESRRA, ESRRB, and ESRRG are known. When ESRRB or ESRRG is forced to be expressed together with OCT4 and SOX2, somatic cells can be reprogrammed (see, for example, Feng B et al., Nat. Cell. Biol., vol. 11, 197-203 (2009)).
[0036] The ESRR family used as the reprogramming factor is not particularly limited, and examples thereof include ESRRB and ESRRG.
[0037] Combinations of reprogramming factors include, but are not limited to, the combinations exemplified in Table 1, as described in WO 2015 / 056804.
[0038] [Table 1]
[0039] The reprogramming factor may have a mutation as long as it has the activity of reprogramming pluripotency induction-resistant somatic cells. When the reprogramming factor has a mutation, the reprogramming factor preferably has 80% or more sequence identity, more preferably 90% or more sequence identity, and even more preferably 95% or more sequence identity to the protein or mRNA specified by the NCBI accession number shown in Table 1.
[0040] Here, the sequence identity of an amino acid sequence is a value indicating the percentage of identity between a target amino acid sequence (subject amino acid sequence) and a reference amino acid sequence (reference amino acid sequence). The sequence identity of a target amino acid sequence to a reference amino acid sequence can be determined, for example, as follows. First, the reference amino acid sequence and the target amino acid sequence are aligned. Here, each amino acid sequence may contain gaps so as to maximize sequence identity. Next, the number of matching amino acids in the reference amino acid sequence and the target amino acid sequence is calculated, and the sequence identity can be determined according to the following formula (1). Sequence identity (%) = number of matching amino acids / total number of amino acids in the target amino acid sequence × 100 … (1)
[0041] Similarly, the sequence identity of a subject base sequence to a reference base sequence can be determined, for example, as follows. First, the reference base sequence and the subject base sequence are aligned. Here, gaps may be included in each base sequence so as to maximize sequence identity. Next, the number of matching bases in the reference base sequence and the subject base sequence is calculated, and the sequence identity can be determined according to the following formula (2). Sequence identity (%) = number of matching bases / total number of bases in the target sequence × 100 … (2)
[0042] In this embodiment, the animal species from which the reprogramming factor is derived may be the same as or different from the animal species from which the somatic cell into which the reprogramming factor is introduced is derived. Those skilled in the art can obtain the amino acid sequence or mRNA sequence of the reprogramming factor of a desired animal species from a database.
[0043] The reprogramming factors may be mRNAs identified by the NCBI accession numbers exemplified in Table 2, proteins encoded by those mRNAs, or genes that transcribe those mRNAs (see, for example, Japanese Patent Publication No. 5098028, Japanese Patent Publication No. 6381442, International Publication No. 2015 / 030111, and International Publication No. 2015 / 056804). The accession numbers shown in Table 1 are human cDNA sequences.
[0044] [Table 2]
[0045] The reprogramming factor of this embodiment may be introduced in the form of a protein, or in the form of a nucleic acid, such as an mRNA or an expression vector, that encodes the protein.
[0046] As described below in the Examples, the reprogramming factors preferably include OCT4, SOX2, KLF4, L-MYC, LIN28 and mP53DD. Furthermore, as described below in the Examples, the reprogramming factors preferably include OCT4, SOX2, KLF4, L-MYC, LIN28, mP53DD, KLF2, KDM4D, GLIS1, and NANOG.
[0047] (Step (a)) In this step, a reprogramming factor is introduced into a mammalian somatic cell, and the cell is cultured in a neural stem cell culture medium to obtain an induced neural stem cell-like cell. Here, the mammal may be an animal resistant to pluripotent induction.
[0048] When the reprogramming factor is a protein or RNA, standard methods such as microinjection and electroporation can be used to introduce the reprogramming factor into cells.
[0049] When the reprogramming factor is a protein, examples of methods for incorporating the reprogramming factor into cells include a method using a protein introduction reagent, a method using a protein introduction domain (PTD) fusion protein, and microinjection.
[0050] Examples of protein introduction reagents that can be used include cationic lipid-type introduction reagents such as BioPORTER (Gelantis), Pro-DeliverIN (OZ Bioscience), Ab-DeliverIN (OZ Bioscience), PULSin Kit (Polyplus-transfection SAS), Proteinfectin (Targeting Systems), and Fuse-It P (NIPPON Genetics); membrane-permeable peptide-type introduction reagents such as Chariot (Active motif), Xfect Protein (Clontech), JBS Transduction Kit (Jena Bioscience), and Cellvader (GE Healthcare); lipid-type introduction reagents such as Profect-1 (Targeting Systems); and HVJ envelope-type introduction reagents such as GenomONETM-Neo (FD) (Cosmo Bio).
[0051] Examples of reagents for transfecting mRNA include TransIT-mRNA Transfection Reagent (TaKaRa) and Lipofectamine MessengerMAX. TM (Thermo Fisher Scientific), Xfect TM Known reagents such as RNA Transfection Reagent (Clonetech) can be used.
[0052] The reprogramming factor may be an expression construct in which a DNA encoding the reprogramming factor is linked to a promoter. The promoter may be one that has activity in a target cell, or may be an expression-inducible promoter whose activity can be induced by a drug or the like.
[0053] The promoter may be, for example, a cytomegalovirus promoter (CMV promoter) or a CMV early enhancer / chicken beta actin (CAG promoter), which have strong promoter activity in almost all cells, or a promoter having tissue-specific promoter activity.
[0054] Examples of expression-inducible promoters include, but are not limited to, doxycycline-inducible promoters, cumate-inducible promoters, heat shock promoters, light-inducible promoters, etc. Alternatively, the expression may be induced by a protein translation stop codon or polyadenine sequence flanked by loxP sites upon the action of Cre recombinase.
[0055] The above-mentioned expression construct may be incorporated into, for example, a transposon vector, an adenovirus vector, an adeno-associated virus vector, a plasmid vector, an episomal vector, or the like.
[0056] The vector is preferably one that does not integrate into the genome, or one that is temporarily integrated into the genome but can be removed from the genome by artificial manipulation.
[0057] For example, when the above construct is incorporated into a transposon vector, it can be easily incorporated into the chromosome of the cell by introducing the vector into the cell and allowing transposase to act. In addition, the above construct incorporated into the chromosome can be excised from the chromosome and removed without leaving any trace by allowing transposase to act. The transposon may be, for example, piggyBac, Sleeping Beauty, Tol II, mariner, etc.
[0058] Alternatively, loxP sequences may be placed on both ends of the above construct, and after establishing iPS cells, the sequences flanked by the loxP sequences may be removed by the action of Cre recombinase.
[0059] The vector is preferably an episomal vector, for example, a vector derived from EBV, SV40, etc., that contains a sequence necessary for autonomous replication in mammalian cells.
[0060] Examples of sequences necessary for autonomous replication in mammalian cells include a replication origin that functions in mammalian cells, and a gene that encodes a protein that binds to the replication origin and controls replication.
[0061] Specifically, for EBV-derived vectors, the replication origin oriP and the EBNA-1 gene can be mentioned, and for SV40 vectors, the replication origin ori and the SV40 large T antigen gene can be mentioned.
[0062] Methods for introducing a vector into a cell include, for example, the lipofection method, the DEAE-dextran method, the calcium phosphate method, the microinjection method, the electroporation method, the gene gun method, the viral vector method, and the like.
[0063] Apparatus for carrying out electroporation that can be used include, for example, NEPA21 (Nepgene), 4D-Nucleofector (Lonza), Neon (Thermo Fisher Scientific), Gene Pulser Xcell (Bio-Rad), and ECM839 (BTX Harvard Apparatus).
[0064] A transfection reagent may be used as a method for introducing a vector into cells. Examples of the transfection reagent include Lipofectamine2000 (Thermo Fisher Scientific), StemFect (STEMGEN), FuGENE6 / HD (Promega), CRISPRMAX (Thermo Fisher Scientific), jetPRIME Kit (Polyplus Transfection), DreamFect (Oz Biosciences), GenePorter3000 (Oz Biosciences), and calcium phosphate method reagents.
[0065] Next, in step (a), the somatic cells of the animal resistant to pluripotency induction into which the reprogramming factor has been introduced are cultured in a neural stem cell culture medium, which preferably contains a MAP kinase inhibitor, a GSK3β inhibitor, and a TGFβ inhibitor.
[0066] The neural stem cell culture medium may further contain Leukemia Inhibitory Factor (LIF) as a differentiation inhibitory factor, and basic fibroblast growth factor (bFGF) as a growth factor.
[0067] Examples of GSK3β inhibitors include CHIR99021, SB-415286, SB-2167, indirubin-3'-monoxime, and Kenpaullone, among which CHIR99021 and Kenpaullone are particularly preferred. The concentration of the GSK inhibitor added to the medium is, for example, 0.1 to 10 μM, preferably 1 to 3 μM.
[0068] Examples of TGF-β inhibitors include A83-01, SB-431542, SB-505124, SB-525334, SD-208, LY-36494, and SJN-2511. Among these, A83-01 is preferred. The concentration of the TGF-β inhibitor added to the medium is, for example, 0.1 to 10 μM, preferably 0.5 to 1 μM.
[0069] The MAP kinase inhibitor may be one that inhibits components of the MAP kinase pathway, such as MAPK, ERK, MEK, MEKK, ERK1, ERK2, Raf, MOS, p21ras, GRB2, SOS, JNK, c-jun, SAPK, JNKK, PAK, RAC, and p38.
[0070] Examples of MAP kinase inhibitors include PD0325901, PD184352, VX-745, SB202190, anisomycin, PD98059, SB203580, U0126, AG126, apigenin, HSP25 kinase inhibitor, 5-iodotubercidin, MAP kinase antisense oligonucleotide, control MAP kinase oligonucleotide, MAP kinase cascade inhibitor, MAP kinase inhibitor set 1, MAP kinase inhibitor set 2, MEK inhibitor set, olomoucine, isoolomoucine, N9 isopropyl olomoucine, p38 Examples of MAP kinase inhibitors include PD169316, SB202474, SB202190 hydrochloride, SB202474 dihydrochloride, SB203580 sulfone, Ioto-SB203580, SB220025, SC68376, SKF-86002, Tyrphostin AG 126, U0124, U0125, ZM336372, etc. (see, for example, Japanese Patent No. 6218229). Among these, PD0325901 is preferred. The concentration of the MAP kinase inhibitor added to the medium is, for example, 0.01 to 10 μM, preferably 0.03 to 1 μM.
[0071] (Step (b)) In this step, the induced neural stem cell-like cells obtained in step (a) are cultured in a proliferation medium to obtain induced pluripotent stem cells.
[0072] As described later in the Examples, the induced neural stem cell-like cells obtained in step (a) can be cultured in a proliferation medium to obtain induced pluripotent stem cells. The proliferation medium may be any medium known for culturing ES cells, but is not limited thereto, and may be any medium suitable for culturing ES cells. As described later in the Examples, the proliferation medium may contain bFGF (FGF2).
[0073] As described below in the Examples, the growth medium may be Dulbecco's modified Eagle's medium containing 20% KSR (Knockout serum replacement, Thermo Fisher Scientific) and 4 to 10 ng / mL bFGF.
[0074] [Induced pluripotent stem cells] In one embodiment, the present invention provides an induced pluripotent stem cell produced by the above-described production method.
[0075] As described later in the Examples, the iPS cells of this embodiment endogenously express pluripotent stem cell markers OCT4, NANOG, SOX2, KLF4, LIN28, ZFP42, TRA-1-60, and SSEA4. The iPS cells of this embodiment can differentiate into endoderm, mesoderm, and ectoderm. The iPS cells of this embodiment can form teratomas and differentiate into differentiated glandular epithelium, blood vessels, cartilage, adipocytes, and nerve cells.
[0076] The iPS cells of this embodiment are produced by expressing the above-mentioned reprogramming factors in somatic cells, and therefore may contain genes encoding the reprogramming factors.
[0077] However, when a gene is introduced using an episomal vector or the like and then the gene is removed during the culture, it is impossible to detect the reprogramming factor.
[0078] There may be differences between the iPS cells of this embodiment and, for example, ES cells in gene expression patterns, etc. However, it is not certain whether such differences exist, and in order to identify such differences and identify the iPS cells of this embodiment based on the gene expression patterns, etc., a significant amount of trial and error would be required, which would be practically impossible. Therefore, it can be said that it is practical to identify the iPS cells of this embodiment by the fact that they have been produced by the above-mentioned production method.
[0079] In addition to the above-mentioned reprogramming factors, in step (a), the efficiency of establishing iPS cells may be improved by contacting somatic cells of the animal resistant to pluripotency induction with a known efficiency-improving substance capable of improving the efficiency of establishing iPS cells.
[0080] As described in WO 2015 / 056804, examples of substances for improving the establishment efficiency of iPS cells include histone deacetylase (HDAC) inhibitors [e.g., valproic acid (VPA) (Nat. Biotechnol., 26(7): 795-797 (2008)), trichostatin A, sodium butyrate, MC 1293, small molecule inhibitors such as M344, and nucleic acid expression inhibitors such as siRNA and shRNA against HDAC (e.g., HDAC1 siRNA Smartpool™ (Millipore), HuSH 29mer shRNA Constructs against HDAC1 (OriGene))], DNA methyltransferase inhibitors (e.g., 5'-azacytidine) (Nat. Biotechnol., 26(7): 795-797 (2008)), G9a histone methyltransferase inhibitors [e.g., BIX-01294 (Cell Stem Cell, 2: 525-528 (2008)), small molecule inhibitors such as siRNA and shRNA against G9a (e.g., G9a siRNA (human) (Santa Cruz Biotechnology)), nucleic acid expression inhibitors such as L-channel calcium agonists (e.g., Bayk8644) (Cell Stem Cell, 3, 568-574 (2008)), UTF1 (Cell Stem Cell, 3, 475-479 (2008)), Wnt Signaling activators (e.g., soluble Wnt3a) (Cell Stem Cell, 3, 132-135 (2008)), 2i / LIF (2i is an inhibitor of mitogen-activated protein kinase signaling and glycogen synthase kinase-3, PloS Biology, 6(10), 2237-2247 (2008)), ES cell-specific miRNAs (e.g., miR-302-367 cluster (Mol. Cell. Biol. doi:10.1128 / MCB.00398-08), miR-302 (RNA (2008) 14: 1-10), miR-291-3p, miR-294 and miR-295 (all Nat.Biotechnol. 27: 459-461 (2009)), 3'-phosphoinositide-dependent kinase-1 (PDK1) acititvator (e.g., PS48 (Cell Stem Cell, 7: 651-655 (2010)), neuropeptide Y (WO 2010 / 147395), prostaglandins (e.g., prostaglandin E2 and prostaglandin J2) (WO 2010 / 068955), and the like, but are not limited thereto.
[0081] In the above steps (a) and (b), the efficiency of iPS cell establishment may be improved by culturing somatic cells, iNSL cells, and iPS cells under hypoxic conditions, for example, under conditions where the oxygen concentration in the atmosphere during cell culture is 18% or less.
[0082] [kit] In one embodiment, the present invention provides a kit for producing induced pluripotent stem cells from somatic cells of a pluripotent induction-resistant animal, the kit comprising: reprogramming factors including an OCT family member, a SOX family member, a KLF family member, a MYC family member, a LIN28 family member, and a P53 function inhibitor; and a neural stem cell culture medium comprising a MAP kinase inhibitor, a GSK3β inhibitor, and a TGFβ inhibitor.
[0083] For example, iPS cells can be produced by introducing the reprogramming factor included in the kit of this embodiment into somatic cells of an animal resistant to pluripotency induction, and then culturing the cells in a neural stem cell culture medium included in the kit of this embodiment. The above-mentioned MAP kinase inhibitor, GSK3β inhibitor, and TGFβ inhibitor may be the inhibitors described above in the production method.
[0084] The above-mentioned kit may further include a growth medium containing bFGF. The growth medium may be any medium capable of culturing ES cells, and may be a known medium.
[0085] By using the kit of this embodiment, induced pluripotent stem cells can be easily produced even from somatic cells of an animal that is resistant to pluripotency induction.
[0086] The reprogramming factors provided in the kit of this embodiment may further include one or more selected from the group consisting of the KDM family, the GLIS family, and NANOG. The reprogramming factors preferably include the OCT family, the SOX family, the KLF family, the MYC family, the LIN28 family, a P53 function inhibitor, the KDM family, the GLIS family, and NANOG.
[0087] The above-mentioned reprogramming factor may be a protein or a nucleic acid encoding a protein, as described above in the production method.
[0088] The P53 function inhibitor included in the kit of this embodiment may be any substance that inhibits the function of P53 protein or inhibits the expression of P53 gene, as described above in the production method.
[0089] The kit of this embodiment may include an expression construct for expressing the reprogramming factor and a non-episomal vector having a nucleic acid encoding EBNA-1. The expression construct may be one in which a gene fragment encoding the reprogramming factor is linked downstream of a promoter as described above in the production method. EXAMPLES
[0090] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.
[0091] In addition, in Figures 1 to 56 of the Examples, E01F and E02M refer to the strain names of marmoset embryonic fibroblasts, and I5061F and CM421F refer to the strain names of adult marmoset fibroblasts. Furthermore, the description of these strain names may refer to cells from which iPS cells and iNSL cells are derived. Furthermore, EP-A refers to the EP-A vector set, and EP-B refers to the EP-B vector set. Furthermore, the descriptions of EP-A and EP-B may refer to the vector set introduced into cells.
[0092] [Experimental Example 1] (Introduction of reprogramming factors and culturing in proliferation medium) After introducing reprogramming factors into marmoset somatic cells, the resulting cells were cultured directly in proliferation medium (ES cell culture medium) without being cultured in neural stem cell culture medium.
[0093] First, we prepared expression constructs for the reprogramming genes inserted into the vectors described below. The reprogramming genes were OCT4, SOX2, KLF4, L-MYC, LIN28, mP53DD, KLF2, NANOG, KDM4D, and GLIS1.
[0094] OCT4, SOX2, KLF4, L-MYC, LIN28, KLF2, NANOG, KDM4D, and GLIS1 are human genes. The mP53DD protein is a dominant-negative form of mouse P53 protein with the C-terminus deleted (Okita K et al., An Efficient Non-viral Method to Generate Integration-Free Human iPS Cells from Cord Blood and Peripheral Blood Cells, Stem Cells, vol.31, 458-466, 2013).
[0095] The expression construct introduced into marmoset somatic cells is shown in Figures 1 and 2. The expression construct has the following structure.
[0096] pCE-hOCT3 / 4, which expresses OCT4, has the ORF of the OCT4 gene downstream of the CAG promoter, and further has the ORF of the EBNA1 gene (EBV Nuclear Antigen 1) and the EBV replication origin OriP downstream of the EBV (Epstein-Barr Virus) promoter.
[0097] pCE-hSK, which expresses SOX2 and KLF4, has the SOX2 ORF, the foot-and-mouth disease virus 2A sequence, and the KLF4 ORF downstream of the CAG promoter, and has the EBNA1 gene ORF and the EBV replication origin OriP downstream of the EBV promoter.
[0098] pCE-hUL, which expresses L-MYC and LIN28, has the L-MYC ORF, the foot-and-mouth disease virus 2A sequence, and the LIN28 ORF downstream of the CAG promoter, and has the EBNA1 gene ORF and the EBV replication origin OriP downstream of the EBV promoter.
[0099] pCE-mP53DD, which expresses mP53DD, has the ORF of mP53DD downstream of the CAG promoter, the ORF of the EBNA1 gene downstream of the EBV promoter, and the EBV replication origin OriP.
[0100] pCXLE-EGFP, which expresses EGFP, has the ORF of EGFP downstream of the CAG promoter, and has the ORF of the EBNA1 gene and the EBV replication origin OriP downstream of the EBV promoter.
[0101] pCXB-EBNA1, which expresses EBNA1, has the ORF of the EBNA1 gene downstream of the CAG promoter.
[0102] pCE-K2N, which expresses KLF2 and NANOG, has the KLF2 ORF, the foot-and-mouth disease virus 2A sequence, and the NANOG ORF downstream of the CAG promoter, and has the EBNA1 gene ORF and the EBV replication origin OriP downstream of the EBV promoter.
[0103] pCE-KdGI, which expresses KDM4D and GLIS1, has the KDM4D ORF, the foot-and-mouth disease virus 2A sequence, and the GLIS1 ORF downstream of the CAG promoter, and has the EBNA1 gene ORF and the EBV replication origin OriP downstream of the EBV promoter.
[0104] The EP-A vector set consists of pCE-hOCT3 / 4, pCE-hSK, pCE-hUL, pCE-mP53DD, pCXLE-EGFP, and pCXB-EBNA1.
[0105] The EP-B vector set consists of pCE-hOCT3 / 4, pCE-hSK, pCE-hUL, pCE-mP53DD, pCXLE-EGFP, pCXB-EBNA1, pCE-K2N, and pCE-KdGI.
[0106] The growth medium used was Dulbecco's modified Eagle medium (DMEM medium) containing 20% KSR (Knockout serum replacement, Thermo Fisher Scientific) and 4 to 10 ng / mL bFGF. The composition of the growth medium is shown in Table 3 below.
[0107] [Table 3]
[0108] The EP-A vector set was introduced into marmoset embryonic fibroblasts (E01F) and cultured directly in proliferation medium without culturing in neural stem cell culture medium. The results are shown in Figure 3.
[0109] Figure 3(a) is a bright-field photograph of cells that were transfected with the EP-A vector set and cultured in a growth medium for four days. Figure 3(b) is a photograph of EGFP fluorescence of cells that were transfected with the EP-A vector set and cultured in a growth medium for four days.
[0110] As a result, it was confirmed that the EP-A vector set was introduced into marmoset cells and that the marker EGFP was expressed.
[0111] The EP-A vector set was introduced into marmoset embryonic fibroblasts (E01F, E02M) and the resulting cells were cultured in ES cell culture medium for 30 days. The results are shown in Figure 4. Figure 4(a) is a photograph of cells after the EP-A vector set was introduced into E01F and cultured in growth medium for 30 days. Figure 4(b) is a photograph of cells after the EP-A vector set was introduced into E02M and cultured in growth medium for 30 days.
[0112] As a result, even when marmoset cells transfected with the EP-A vector set were directly cultured in ES cell culture medium without being cultured in neural stem cell culture medium, no cell colonies or cell clusters were observed. This result revealed that marmoset iPS cells would not be formed even if marmoset cells were cultured in ES cell culture medium after expressing reprogramming factors.
[0113] [Experimental Example 2] (Introduction of reprogramming factors and culturing in neural stem cell culture medium) We introduced reprogramming factors into marmoset embryonic fibroblasts and cultured them in neural stem cell culture medium to dedifferentiate the marmoset cells.
[0114] The process for establishing iPS cells from marmoset somatic cells is shown in Figure 5. First, the reprogramming factor expression construct was introduced into marmoset somatic cells by electroporation. Then, the obtained cells were cultured using Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS).
[0115] The resulting cells were then cultured using MEF as feeder cells, and then cultured in neural stem cell culture medium.
[0116] The neural stem cell culture medium used contained a MAP kinase inhibitor (PD0325901), a GSK3β inhibitor (CHIR99021), and a TGFβ inhibitor (A83-01). The composition of the neural stem cell culture medium is shown in Table 4 below.
[0117] [Table 4]
[0118] In Table 4, DMEM / F12 medium is a medium in which DMEM and Ham's F-12 are mixed at a ratio of 1:1. Neurobasal medium is manufactured by Thermo Fisher Scientific.
[0119] Marmoset embryonic fibroblasts (E01F, E02M) were transfected with the EP-A vector set or the EP-B vector set and cultured in a neural stem cell culture medium. The results are shown in FIG.
[0120] Figure 6(a) is a photograph of a colony formed after E01F was introduced with an EP-A vector set and then cultured in neural stem cell culture medium. Figure 6(b) is a photograph of a colony formed after E01F was introduced with an EP-B vector set and then cultured in neural stem cell culture medium. Figure 6(c) is a photograph of a colony formed after E02M was introduced with an EP-A vector set and then cultured in neural stem cell culture medium. Figure 6(d) is a photograph of a colony formed after E02M was introduced with an EP-A vector set and then cultured in neural stem cell culture medium.
[0121] As a result, it was revealed that marmoset cells into which either the EP-A vector set or the EP-B vector set was introduced formed colonies.
[0122] Furthermore, the colony-forming ability of marmoset cells into which the EP-A vector set or the EP-B vector set was introduced was calculated. The results are shown in Figure 7. Figure 7 is a graph showing the results of calculating the colony-forming ability when marmoset embryonic fibroblasts were used.
[0123] The above colonies were also subjected to alkaline phosphatase staining. The results are shown in Figure 8. Figure 8(a) shows the results of alkaline phosphatase staining of colonies obtained by introducing E01F into an EP-A vector set and culturing in a neural stem cell culture medium. Figure 8(b) shows the results of alkaline phosphatase staining of colonies obtained by introducing E01F into an EP-B vector set and culturing in a neural stem cell culture medium.
[0124] As a result, it was revealed that the colonies of marmoset cells into which the EP-A vector set or the EP-B vector set had been introduced were stained with alkaline phosphatase staining.
[0125] These results suggest that these colonies are dedifferentiated and in an undifferentiated state. Hereafter, the cells that form these colonies may be referred to as induced neural stem cell-like cells, iNSLCs, or iNSL cells.
[0126] [Experimental Example 3] (Establishment of marmoset iPS cells) Marmoset embryonic fibroblasts were transfected with reprogramming factors and cultured in neural stem cell culture medium, followed by culture in proliferation medium (ES cell culture medium) to establish marmoset iPS cells. The neural stem cell culture medium and proliferation medium were the same as those used in Experimental Examples 1 and 2.
[0127] The EP-A vector set or the EP-B vector set was introduced into marmoset embryonic fibroblasts (E01F, E02M). The resulting cells were then cultured in a neural stem cell culture medium, and then cultured in a proliferation medium.
[0128] The results are shown in FIG. 9. FIG. 9(a) is a photograph of a colony formed by introducing an EP-A vector set into marmoset embryonic fibroblasts (E01F) and culturing them in a neural stem cell culture medium. FIG. 9(b) is a photograph of a colony formed by introducing an EP-A vector set into marmoset embryonic fibroblasts (E01F) and culturing them in a neural stem cell culture medium, followed by culturing them in a proliferation medium. FIG. 9(c) is a photograph of a colony formed by introducing an EP-B vector set into marmoset embryonic fibroblasts (E02M) and culturing them in a neural stem cell culture medium. FIG. 9(d) is a photograph of a colony formed by introducing an EP-B vector set into marmoset embryonic fibroblasts (E02M) and culturing them in a neural stem cell culture medium, followed by culturing them in a proliferation medium.
[0129] As a result, when reprogramming factors were introduced into marmoset embryonic fibroblasts, which were then cultured in neural stem cell culture medium and then in proliferation medium, colonies similar in shape to those formed by ES cells were observed.
[0130] Next, colonies of marmoset ES cells (No. 40 ESC) and the above-mentioned marmoset iPS cells (A-2-2, A-2-6, A-2-7 derived from E01F, and B-0-6, B-0-7, B-0-11 derived from E02M) were subjected to Hoechst staining and immunostaining using anti-TRA-1-60 antibody and anti-SSEA4 antibody. TRA-1-60 and SSEA4 are genes expressed in ES cells. The results are shown in FIG. 10.
[0131] 10 shows the results of analyzing the expression of ES cell markers in marmoset iPS cells, which revealed that these marmoset iPS cells expressed TRA-1-60 and SSEA4, similar to ES cells.
[0132] Next, the above-mentioned colonies of marmoset iPS cells were subjected to alkaline phosphatase staining. The results are shown in FIG. 11. FIG. 11 shows the results of subjecting marmoset iPS cells to alkaline phosphatase staining. As a result, it was revealed that these colonies were stained with alkaline phosphatase staining, similar to undifferentiated cells.
[0133] Next, the above-mentioned marmoset iPS cell colonies were subjected to Hoechst staining and immunostaining using anti-OCT4 antibody and anti-NANOG antibody. The results are shown in Figure 12. Figure 12 shows the results of analyzing the expression of ES cell markers in marmoset iPS cells. As a result, it was revealed that these marmoset iPS cell colonies expressed OCT4 and NANOG, similar to ES cells.
[0134] Next, the expression of endogenous OCT4, endogenous NANOG, endogenous SOX2, endogenous KLF4 genes, ZFP42 gene (Zinc finger protein 42), DPPA gene (Developmental Pluripotency Associated 2), and TERT gene (Telomerase Reverse Transcriptase) was analyzed by qRT-PCR for the above-mentioned marmoset iPS cells, marmoset ES cells (No. 40, DSY127), and marmoset embryonic fibroblasts. The results are shown in Figures 13 and 14.
[0135] Figures 13 and 14 show the results of analyzing the expression of ES cell markers in marmoset iPS cells. As a result, it was revealed that marmoset iPS cells, like marmoset ES cells, endogenously express OCT4, NANOG, SOX2, KLF4, DRPA5, ZFP42, and TERT genes.
[0136] Next, whether or not the vector contained in the EP-A vector set or the EP-B vector set remained in the marmoset iPS cells was analyzed by PCR. The results are shown in Figure 15. Figure 15 shows the results of analyzing the presence or absence of expression vectors in marmoset iPS cells.
[0137] As a result, it was revealed that for E01F A-2-2 iPSCs, E01F A-2-3 iPSCs, E01F A-2-5 iPSCs, E01F A-2-6 iPSCs, E01F A-2-7 iPSCs, E02M B-0-6 iPSCs, and E02M B-0-7 iPSCs, no EP-A vector set or EP-B vector set remained in the cells.
[0138] These results demonstrated that when marmoset cells into which the EP-A vector set or EP-B vector set had been introduced were cultured in neural stem cell culture medium and then in proliferation medium, ES cell marker genes were expressed even if the vector set was lost.
[0139] [Experimental Example 4] (Pluripotency of marmoset iPS cells) The marmoset iPS cells obtained in Experimental Example 3 were differentiated into endoderm, mesoderm, and ectoderm, and the expression of marker genes for each germ layer was analyzed to verify the pluripotency of the marmoset iPS cells.
[0140] First, marmoset iPS cells (A-2-2, A-2-6, A-2-7, B-0-7) were cultured in suspension and differentiated into each germ layer.
[0141] Next, the expression of alpha-fetoprotein (AFP) in the endoderm, α-smooth muscle actin (αSMA) in the mesoderm, microtubule associated protein 2 (MAP2) and βIII-tubulin in the ectoderm was analyzed using antibodies against each protein. Hoechst staining was also performed at the same time. The results are shown in Figure 16.
[0142] Figure 16 shows the results of analyzing the expression of markers in the three germ layers differentiated from marmoset iPS cells. As a result, it was revealed that each germ layer formed from marmoset iPS cells expressed marker genes characteristic of that germ layer.
[0143] In addition, embryoid bodies formed from marmoset iPS cells were cultured for 2 or 4 weeks in KnockOut Serum Replacement medium (KSR medium) or medium containing 10% fetal bovine serum, and then the expression of AFP was analyzed by qRT-PCR. The results are shown in Figures 17 and 18.
[0144] Fig. 17 shows the results of analyzing the expression of AFP in marmoset iPS cells cultured in KSR medium, and Fig. 18 shows the results of analyzing the expression of AFP in marmoset iPS cells cultured in a medium containing FBS.
[0145] 17 and 18, EB indicates embryoid bodies, 2w indicates two weeks later, and 4w indicates four weeks later. As a result, it was revealed that the embryoid bodies formed from marmoset iPS cells expressed AFP.
[0146] Furthermore, the obtained marmoset iPS cells (A-2-2, A-2-7, B-0-7) were injected into the testes of immunodeficient mice (NOD / SCID). After 2 to 3 months, teratomas formed in the testes were removed and tissues differentiated from the endoderm, mesoderm, and ectoderm were observed.
[0147] More specifically, glandular epithelium differentiated from endoderm, blood vessels, cartilage, and adipocytes differentiated from mesoderm were observed by hematoxylin-eosin staining (HE staining), and nerve cells differentiated from ectoderm were observed by HE staining and immunostaining with an antibody against neurofilament 200 kDa. The results are shown in Figure 19.
[0148] Figure 19 shows the results of analyzing teratomas formed from marmoset iPS cells, revealing that differentiated glandular epithelium, blood vessels, cartilage, adipocytes, and nerve cells were formed in the teratomas.
[0149] [Experimental Example 5] (Establishment of iPS cells from adult marmoset cells) EP-A or EP-B vector set was introduced into adult marmoset fibroblasts and cultured in neural stem cell culture medium to establish iNSL cells. The obtained iNSL cells were then cultured in a proliferation medium to establish iPS cells.
[0150] Marmoset iNSL cells were established by the above-mentioned method using adult marmoset fibroblasts (I5061F, CM421F). The results are shown in Figure 20. Figure 20 is a photograph of iNSL cells derived from adult marmoset fibroblasts.
[0151] As a result, it was revealed that iNSL cells derived from adult marmoset fibroblasts formed cell clusters and colonies.
[0152] Next, the colony-forming ability of iNSL cells derived from adult marmoset fibroblasts was calculated. The results are shown in Figure 21. Figure 21 is a diagram showing the colony-forming ability of iNSL cells derived from adult marmoset fibroblasts.
[0153] In Figure 21, "+VPA" indicates that a histone deacetylase inhibitor (Valproic Acid) was added for 2 days. As a result, it was revealed that iNSL cells could be established reproducibly from adult marmoset fibroblasts.
[0154] Next, the iNSL cells were stained with alkaline phosphatase. The results are shown in Figure 22. Figure 22 shows the results of alkaline phosphatase staining of iNSL cells derived from adult marmoset fibroblasts.
[0155] As a result, it was revealed that iNSL cells derived from adult marmoset fibroblasts express alkaline phosphatase, indicating that iNSL cells derived from adult marmoset fibroblasts have undifferentiated properties.
[0156] Next, in the same manner as in Experimental Example 3, the above-mentioned iNSL cells were cultured in a proliferation medium to obtain marmoset iPS cells. The results are shown in Figure 23. Figure 23 is a photograph of a colony of marmoset iPS cells derived from fibroblasts of an adult marmoset. As a result, it was revealed that the marmoset iPS cells cultured in the proliferation medium formed colonies similar to those of ES cells.
[0157] The obtained marmoset iPS cells were then subjected to alkaline phosphatase staining. The results are shown in Figure 24. Figure 24 shows the results of alkaline phosphatase staining of iPS cells derived from adult marmoset fibroblasts. The results suggested that the established marmoset iPS cells were undifferentiated.
[0158] The obtained marmoset iPS cells were then immunostained using anti-TRA-1-60 antibody and anti-SSEA4 antibody. At the same time, staining was performed using Hoechst. The results are shown in FIG.
[0159] 25 shows the results of analyzing the expression of ES cell markers in marmoset iPS cells derived from adult marmoset fibroblasts. As a result, it was revealed that the obtained marmoset iPS cells expressed TRA-1-60 and SSEA4, similar to ES cells.
[0160] Next, the endogenous OCT4, NANOG, SOX2, KLF4, and Lin28 gene expressions, as well as ZFP42 gene, DPPA gene, and TERT gene expressions in the obtained marmoset iPS cells were analyzed by qRT-PCR. The results are shown in Figures 26 to 29.
[0161] 26 to 29 are diagrams showing the results of analyzing the expression of ES cell markers in marmoset iPS cells derived from adult marmoset fibroblasts. As a result, it was revealed that the obtained marmoset iPS cells express the above-mentioned genes, similar to marmoset ES cells.
[0162] Next, the obtained marmoset iPS cells were differentiated into endoderm, mesoderm, and ectoderm in the same manner as in Experimental Example 4, and the expression of marker genes for each germ layer was analyzed.
[0163] Next, the expression of AFP in the endoderm, αSMA in the mesoderm, MAP2 and βIII-tubulin in the ectoderm were analyzed using antibodies against each protein. Hoechst staining was also performed at the same time. The results are shown in Figures 30 and 31.
[0164] Figures 30 and 31 show the results of analyzing the expression of markers in the three germ layers differentiated from marmoset iPS cells derived from adult marmoset fibroblasts. As a result, it was revealed that each germ layer formed by differentiation from the obtained marmoset iPS cells expressed marker genes characteristic of each germ layer.
[0165] Furthermore, teratomas were produced from the obtained marmoset iPS cells in the same manner as in Experimental Example 4, and tissues differentiated from the endoderm, mesoderm, and ectoderm were observed. Glandular epithelium differentiated from the endoderm and blood vessels differentiated from the mesoderm were observed by HE staining, and nerve cells differentiated from the ectoderm were observed by HE staining and immunostaining with an antibody against neurofilament 200 kDa. The results are shown in Figure 32.
[0166] Figure 32 shows the results of analyzing teratomas formed from marmoset iPS cells derived from adult marmoset fibroblasts, revealing that differentiated glandular epithelium, blood vessels, and nerve cells are formed in the teratomas.
[0167] The obtained marmoset iPS cells were also analyzed by PCR to determine whether the vectors contained in the EP-A vector set or the EP-B vector set remained. The results are shown in FIG.
[0168] Fig. 33 shows the results of an analysis of whether vectors remain in marmoset iPS cells derived from adult marmoset fibroblasts, which revealed that no vectors remain in the obtained marmoset iPS cells.
[0169] [Experimental Example 6] (Analysis of gene expression patterns in iNSL cells) We transfected marmoset embryonic fibroblasts or adult marmoset fibroblasts with the EP-A or EP-B vector set, then cultured them in neural stem cell culture medium to obtain induced neural stem cell-like cells (iNSL cells). We analyzed the gene expression patterns and differentiation potential of the obtained iNSL cells into neural cells.
[0170] First, the EP-A vector set or the EP-A vector set was introduced into marmoset embryonic fibroblasts, and then the cells were cultured in a neural stem cell culture medium. The results are shown in Figure 34. Figure 34 is a photograph of marmoset iNSL cells. As a result, it was confirmed that iNSL cells were obtained.
[0171] Subsequently, whether or not the EP-A vector set or the EP-B vector set remained in the obtained iNSL cells was analyzed by PCR. The results are shown in Figure 35. Figure 35 shows the results of analyzing the vectors remaining in the iNSL cells.
[0172] As a result, it was revealed that the EP-A vector set or the EP-B vector set remained in the iNSL cells that had been passaged 10 times after the introduction of the vector set.
[0173] Next, the gene expression patterns of the obtained iNSL cells were analyzed by qRT-PCR. The results are shown in Figures 36 and 37. Figure 36 shows the results of analyzing the expression of endogenous OCT4, NANOG, SOX2, KLKF4, and ZFP42 in iNSL cells. Figure 37 shows the results of analyzing the expression of DPPA5 and TERT in iNSL cells.
[0174] As a result, it was revealed that the obtained iNSL cells endogenously expressed SOX2 and TERT, but did not endogenously express OCT4, NANOG, KLF4, ZFP42, or DPPA5.
[0175] Next, the gene expression levels of the obtained iNSL cells, including the endogenous gene expression and the exogenous (gene expression by the vector set) gene expression, were analyzed by qRT-PCR. Figure 38 shows the results of analyzing the expression of endogenous and exogenous OCT4, NANOG, KLF4, and Lin28 in iNSL cells.
[0176] As a result, it was revealed that the gene expression levels, which were the combined expression levels of endogenous and exogenous genes, were OCT4, KLF4, and Lin28, but not NANOG.
[0177] Next, the expression of neural stem cell markers PAX6 (Paired box 6), SOX1 (Sry-type HMG box 1), and ZFP521 (Zinc Finger Protein 521) was analyzed for the obtained iNSL cells by qRT-PCR. The results are shown in Figures 39 and 40.
[0178] Figure 39 shows the results of analyzing the expression of PAX6 in iNSL cells. Figure 40 shows the results of analyzing the expression of SOX1 and ZFP521 in iNSL cells. As a result, it was revealed that PAX6 was not expressed in marmoset ES cells, but the obtained induced neural stem cells expressed PAX6, SOX1, and ZFP521.
[0179] Next, the expression of mesodermal marker T (TBX T) and endoderm marker SOX17 (Sry-type HMG box 17) was analyzed by qRT-PCR for the obtained induced neural stem cells. The results are shown in Figure 41.
[0180] 41 shows the results of analyzing the expression of T and SOX17 in iNSL cells. As a result, it was confirmed that T and SOX17 were expressed in marmoset ES cells but not in the obtained induced neural stem cells.
[0181] Next, the differentiation ability of marmoset ES cells, marmoset iPS cells, and marmoset induced neural stem cells into neural stem cells was analyzed by an unbiased neuronal differentiation assay. Figure 42 shows the schedule of the neuronal differentiation assay. Specifically, the cells were cultured in suspension for 7 days, followed by adhesion culture for 7 days. The results are shown in Figures 43 and 44.
[0182] Fig. 43 shows the results of Hoechst staining and immunostaining with anti-βIII-tubulin antibody of the cells differentiated from the obtained induced neural stem cells, which demonstrated that the cells differentiated from the obtained induced neural stem cells were differentiated into nerve cells.
[0183] Figure 44 is a graph showing the percentage of cells in which expression of βIII-tubulin was observed among cells differentiated into nerve cells. As a result, it was revealed that cells differentiated from marmoset ES cells and marmoset iPS cells do not express βIII-tubulin, but cells differentiated from marmoset induced neural stem cells express βIII-tubulin.
[0184] These results demonstrated that iNSL cells obtained by introducing the EP-A or EP-B vector set into adult marmoset fibroblasts and culturing them in neural stem cell culture medium acquire the properties of neural stem cells.
[0185] Furthermore, when iNSL cells were continuously cultured in neural stem cell culture medium without being transferred to a proliferation medium, the iNSL cells retained the vector but did not acquire the characteristics of neural stem cells and did not acquire the characteristics of ES cells.
[0186] These results demonstrated that although it is not possible to directly generate iPS cells from adult somatic cells of animals resistant to pluripotency induction, it is possible to first dedifferentiate the cells into neural stem cells and then further dedifferentiate them into iPS cells.
[0187] [Experimental Example 7] (Gene profiling of marmoset iPS cells and iNSL cells) Clustering analysis was performed on the gene expression profiles of marmoset ES cells, iPS cells, and iNSL cells.
[0188] Clustering analysis was performed on marmoset ES cells, iPS cells, and iNSL cells based on the comprehensive gene expression profiles. The results are shown in Figure 45. As a result, it was revealed that marmoset iPS cells are highly similar to marmoset ES cells, and marmoset iNSL cells are highly similar to marmoset fibroblasts.
[0189] Next, the expression levels of 40 genes that reflect the similarity of each cluster were analyzed in each cell. The results are shown in Figure 46. As a result, genes with characteristic expression levels in marmoset iPS cells and marmoset induced neural stem cells were extracted.
[0190] A principal component analysis was performed on the gene expression profile of each cell. The results are shown in Figure 47. As a result, it was revealed that each cell can be divided into the following groups: fibroblasts, ES cells, iPS cells, and induced neural stem cells.
[0191] [Experimental Example 8] (Establishment of canine iPS cells) The EP-B vector set was introduced into canine fibroblasts to establish canine iPS cells.
[0192] The results are shown in Figure 48. Figure 48 is a photograph of the colonies formed by canine iPS cells. As a result, it was revealed that canine iPS cells formed colonies similar to those formed by ES cells.
[0193] The expression of ES cell markers in the obtained canine iPS cells was analyzed. The results are shown in Figure 49. Figure 49 shows the results of RT-PCR analysis of the expression of OCT4, SOX2, and NANOG in canine iPS cells.
[0194] As a result, it was revealed that canine iPS cells expressed OCT4, SOX2, and NANOG, suggesting that canine iPS cells have similar characteristics to ES cells.
[0195] Canine iPS cells were injected into the testes of immunodeficient mice (NOD / SCID), and teratomas formed in the testes were excised 2 to 3 months later and observed. The results are shown in FIG.
[0196] The obtained teratomas were stained with hematoxylin and eosin to observe each tissue. The results are shown in Figure 51. Figure 51 shows the results of analyzing bone, cartilage, nerve cells, retina, sebaceous gland, hair follicle epithelium, and glandular tissue.
[0197] The obtained canine iPS cells were analyzed by PCR to determine whether the introduced vector remained or not. The results are shown in Figure 52. As a result, it was confirmed that the expression vector did not remain in the canine iPS cells.
[0198] [Experimental Example 9] (Establishment of porcine iPS cells) The EP-B vector set was introduced into porcine fibroblasts to establish porcine iNSL cells and porcine iPS cells.
[0199] Figure 53 is a photograph of the obtained colonies of porcine iPS cells. It was revealed that porcine iPS cells form colonies similar to those formed by ES cells.
[0200] Next, the expression of ES cell markers in porcine iPS cells and porcine iNSL cells was analyzed by RT-PCR. Figure 54 shows the results of analyzing the expression of OCT4, SOX2, and NANOG in porcine iNSL cells and porcine iPS cells.
[0201] As a result, it was revealed that porcine iPS cells expressed OCT4, SOX2, and NANOG, and that porcine iNSL cells expressed SOX2.
[0202] [Experimental Example 10] (Establishment of ferret iPS cells) The EP-B vector set was introduced into ferret fibroblasts to establish ferret iNSL cells and ferret iPS cells.
[0203] Figure 55 is a photograph of the resulting colonies of ferret iPS cells. It was revealed that ferret iPS cells form colonies similar to those formed by ES cells.
[0204] Next, the expression of ES cell markers in ferret iPS cells was analyzed. Figure 56 shows the results of RT-PCR analysis of the expression of OCT4, SOX2, and NANOG in ferret iNSL cells and ferret iPS cells.
[0205] As a result, it was revealed that ferret iPS cells expressed OCT4, SOX2, and NANOG, and ferret iNSL cells expressed SOX2. [Industrial Applicability]
[0206] According to the present invention, a new technique for establishing iPS cells from mammalian somatic cells can be provided.
Claims
1. A step of introducing a reprogramming factor into a mammalian somatic cell, and culturing the cell in a neural stem cell culture medium containing a MAP kinase inhibitor, a GSK3β inhibitor, and a TGFβ inhibitor to obtain an induced neural stem cell-like cell; Culturing the induced neural stem cell-like cells in an ES cell culture medium to obtain induced pluripotent stem cells, The method for producing induced pluripotent stem cells, wherein the reprogramming factors include the OCT family, the SOX family, the KLF family, the MYC family, the LIN28 family, a P53 function inhibitor, the KDM family, the GLIS family and NANOG.
2. The method for producing induced pluripotent stem cells according to claim 1 , wherein the somatic cells are derived from an adult.
3. The method for producing induced pluripotent stem cells according to claim 1 or 2, wherein the ES cell culture medium contains bFGF.
4. the mammal is a pluripotent induced resistant animal, The method for producing induced pluripotent stem cells according to any one of claims 1 to 3, wherein the induced pluripotent resistant animal is a marmoset, a dog, a pig or a ferret.
5. The method for producing induced pluripotent stem cells described in Claim 4, wherein the pluripotent induced resistant animal is a dog.
6. Reprogramming factors including the OCT family, the SOX family, the KLF family, the MYC family, the LIN28 family, a P53 function inhibitor, the KDM family, the GLIS family, and NANOG; A neural stem cell culture medium comprising a MAP kinase inhibitor, a GSK3β inhibitor and a TGFβ inhibitor.
7. The kit of claim 6 , further comprising an ES cell culture medium containing bFGF.
8. The kit according to claim 6 or 7, wherein the somatic cells are of adult origin.
9. The kit according to any one of claims 6 to 8, wherein the pluripotent induced resistant animal is a marmoset, a dog, a pig or a ferret.
10. The kit described in claim 9, wherein the pluripotent induced resistant animal is a dog.
11. A step of producing induced pluripotent stem cells by the production method according to any one of claims 1 to 5; and differentiating the induced pluripotent stem cells to obtain somatic cells.
Citation Information
Patent Citations
Highly efficient method for establishing artificial pluripotent stem cell
WO2013176233A1
